Global TCR Therapies Market | Industry Analysis | Market Size | 2035

1. Global TCR-based Therapy Market(2022-2035) Growing burden and unaddressed complex treatment needs of cancer patients have paved the way for more effective, safe and versatile alternatives, such as TCR therapies. Driven by Kimmtrak® approval, promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is anticipated to witness significant growth in the mid to long-term. key Drivers and Trends ▪ ▪ ▪ A detailed assessment of the current market landscape of TCR-based therapies. An analysis of the popular target antigens related to hematological malignancies and solid tumors. A detailed analysis of completed, ongoing and planned clinical studies related to TCR-based therapies. An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to TCR-based therapies. Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above). An analysis of various types of partnership that have been inked between several stakeholders in the domain of TCR-based therapies. An analysis of the investments that have been made into companies that have proprietary TCR-based products / technologies. An in-depth analysis of patents related to TCR-based therapies, filed / granted till 2022. A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space. An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. A review of the key promotional strategies being adopted by the developers of the approved TCR-based therapies. Elaborate profiles of the several leading players in the domain of TCR cell therapies. ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪

2. key Market Segments ▪ Target Indication(s) ▪ Nasopharyngeal Carcinoma ▪ Multiple Myeloma ▪ Head and Neck Carcinoma ▪ Sarcoma, Melanoma ▪ Acute Myeloid Leukemia ▪ Lung Cancer ▪ Ovarian Cancer ▪ Merkel Cell Cancer ▪ Target Antigen ▪ NY-ESO-1 ▪ EBV ▪ gp100 ▪ Others ▪ Key Geographical Regions ▪ North America ▪ Europe ▪ Asia Pacific ▪ Latin America ▪ Middle East and North Africa ▪ Rest of the World Key Market Insights ▪ More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders More than 90% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature; NY-ESO-1 and MAGE have emerged as the most popular target antigens In the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR-based therapies; extensive efforts are underway to improve the successive generations of such therapies Close to 60 scientists from renowned universities are presently involved in the clinical development of TCR-based therapies; majority of these KOLs are primarily based in the US and China Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development A growing interest in this field is reflected from the increase in the partnership activity, involving both international and indigenous stakeholders; majority of such deals were signed between players based in North America Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion, across 140 instances, since 2007 More than 75 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51%, in the next decade ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪